Loading...

BioCryst Pharmaceuticals

Nasdaq:BCRX
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BCRX
Nasdaq
$407M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The last earnings update was 45 days ago. More info.


Add to Portfolio Compare Print
  • BioCryst Pharmaceuticals has significant price volatility in the past 3 months.
BCRX Share Price and Events
7 Day Returns
8.9%
NasdaqGS:BCRX
5.9%
US Biotechs
2.2%
US Market
1 Year Returns
-34%
NasdaqGS:BCRX
-4.3%
US Biotechs
3.8%
US Market
BCRX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioCryst Pharmaceuticals (BCRX) 8.9% 11.1% -50.7% -34% 29.9% -70.5%
US Biotechs 5.9% 4.6% 1.7% -4.3% 22.4% 12%
US Market 2.2% 4.2% 4.4% 3.8% 43% 40.9%
1 Year Return vs Industry and Market
  • BCRX underperformed the Biotechs industry which returned -4.3% over the past year.
  • BCRX underperformed the Market in United States of America which returned 3.8% over the past year.
Price Volatility
BCRX
Industry
5yr Volatility vs Market

Value

 Is BioCryst Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BioCryst Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BioCryst Pharmaceuticals.

NasdaqGS:BCRX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.8%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:BCRX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.32
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.325 (1 + (1- 21%) (20.65%))
1.362
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.36
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.362 * 5.96%)
10.85%

Discounted Cash Flow Calculation for NasdaqGS:BCRX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BioCryst Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:BCRX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.85%)
2019 -105.50 Analyst x2 -95.17
2020 -93.50 Analyst x2 -76.09
2021 -142.00 Analyst x1 -104.25
2022 -74.00 Analyst x1 -49.01
2023 50.00 Analyst x1 29.87
2024 69.84 Est @ 39.67% 37.64
2025 89.80 Est @ 28.59% 43.66
2026 108.51 Est @ 20.83% 47.60
2027 125.22 Est @ 15.4% 49.55
2028 139.74 Est @ 11.6% 49.89
Present value of next 10 years cash flows $-66.31
NasdaqGS:BCRX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $139.74 × (1 + 2.73%) ÷ (10.85% – 2.73%)
$1,767.98
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,767.98 ÷ (1 + 10.85%)10
$631.14
NasdaqGS:BCRX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-66.31 + $631.14
$564.83
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $564.83 / 110.31
$5.12
NasdaqGS:BCRX Discount to Share Price
Calculation Result
Value per share (USD) From above. $5.12
Current discount Discount to share price of $3.69
= -1 x ($3.69 - $5.12) / $5.12
27.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price BioCryst Pharmaceuticals is available for.
Intrinsic value
28%
Share price is $3.69 vs Future cash flow value of $5.12
Current Discount Checks
For BioCryst Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • BioCryst Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • BioCryst Pharmaceuticals's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioCryst Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioCryst Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:BCRX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.00
NasdaqGS:BCRX Share Price ** NasdaqGS (2019-06-21) in USD $3.69
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,094 Publicly-Listed Companies 17.87x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioCryst Pharmaceuticals.

NasdaqGS:BCRX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:BCRX Share Price ÷ EPS (both in USD)

= 3.69 ÷ -1.00

-3.67x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioCryst Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • BioCryst Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does BioCryst Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGS:BCRX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.67x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
28.7%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.04x
United States of America Market PEG Ratio Median Figure of 2,134 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BioCryst Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioCryst Pharmaceuticals's assets?
Raw Data
NasdaqGS:BCRX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.20
NasdaqGS:BCRX Share Price * NasdaqGS (2019-06-21) in USD $3.69
United States of America Biotechs Industry PB Ratio Median Figure of 431 Publicly-Listed Biotechs Companies 3.01x
United States of America Market PB Ratio Median Figure of 5,255 Publicly-Listed Companies 1.81x
NasdaqGS:BCRX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:BCRX Share Price ÷ Book Value per Share (both in USD)

= 3.69 ÷ 0.20

18.08x

* Primary Listing of BioCryst Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioCryst Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess BioCryst Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BioCryst Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BioCryst Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
28.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioCryst Pharmaceuticals expected to grow at an attractive rate?
  • BioCryst Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • BioCryst Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • BioCryst Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:BCRX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:BCRX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 28.7%
NasdaqGS:BCRX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 53.8%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.9%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:BCRX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:BCRX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 198 31 4
2022-12-31 95 -82 5
2021-12-31 41 -130 5
2020-12-31 39 -76 -120 8
2019-12-31 15 -119 -135 8
NasdaqGS:BCRX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 23 -100 -107
2018-12-31 21 -93 -101
2018-09-30 22 -79 -93
2018-06-30 29 -56 -79
2018-03-31 20 -52 -77
2017-12-31 25 -41 -66
2017-09-30 30 -36 -51
2017-06-30 29 -42 -47
2017-03-31 31 -43 -47
2016-12-31 26 -53 -55
2016-09-30 22 -62 -69
2016-06-30 25 -58 -72

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BioCryst Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • BioCryst Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:BCRX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from BioCryst Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:BCRX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.13 0.52 -1.24 4.00
2022-12-31 -0.69 -0.15 -1.29 4.00
2021-12-31 -1.10 -0.64 -1.55 4.00
2020-12-31 -1.04 -0.69 -1.35 7.00
2019-12-31 -1.21 -1.14 -1.27 7.00
NasdaqGS:BCRX Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.00
2018-12-31 -0.98
2018-09-30 -0.93
2018-06-30 -0.83
2018-03-31 -0.86
2017-12-31 -0.78
2017-09-30 -0.65
2017-06-30 -0.62
2017-03-31 -0.63
2016-12-31 -0.75
2016-09-30 -0.93
2016-06-30 -0.98

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BioCryst Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess BioCryst Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioCryst Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BioCryst Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioCryst Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioCryst Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare BioCryst Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BioCryst Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
BioCryst Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioCryst Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:BCRX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 22.56 -106.53 21.84
2018-12-31 20.65 -101.25 18.51
2018-09-30 21.81 -93.36 19.02
2018-06-30 29.12 -78.90 18.74
2018-03-31 19.73 -77.34 13.78
2017-12-31 25.19 -65.78 13.93
2017-09-30 30.28 -50.74 11.80
2017-06-30 29.28 -47.14 11.21
2017-03-31 30.97 -46.53 11.10
2016-12-31 26.35 -55.14 11.25
2016-09-30 21.97 -68.78 11.41
2016-06-30 25.20 -71.87 11.39
2016-03-31 46.25 -50.69 12.20
2015-12-31 48.26 -43.02 13.05
2015-09-30 49.10 -36.56 12.37
2015-06-30 41.35 -30.67 11.46
2015-03-31 16.98 -50.22 9.93
2014-12-31 13.61 -45.19 7.46
2014-09-30 18.73 -38.95 6.83
2014-06-30 17.88 -38.22 6.60
2014-03-31 17.24 -35.74 6.02
2013-12-31 17.33 -30.11 6.01
2013-09-30 10.87 -35.73 5.02
2013-06-30 14.24 -37.43 5.03
2013-03-31 17.63 -37.54 5.21
2012-12-31 26.29 -39.08 9.13
2012-09-30 27.42 -41.22 6.01
2012-06-30 26.90 -45.98 7.37

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BioCryst Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BioCryst Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BioCryst Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BioCryst Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioCryst Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BioCryst Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioCryst Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioCryst Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioCryst Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BioCryst Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioCryst Pharmaceuticals Company Filings, last reported 2 months ago.

NasdaqGS:BCRX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 22.51 84.06 107.56
2018-12-31 49.24 61.82 104.47
2018-09-30 72.87 61.70 120.32
2018-06-30 46.18 51.69 80.74
2018-03-31 62.05 53.21 91.31
2017-12-31 83.77 54.72 114.40
2017-09-30 100.63 54.52 161.62
2017-06-30 24.08 54.16 80.67
2017-03-31 38.53 53.94 98.68
2016-12-31 1.58 53.72 54.65
2016-09-30 3.99 53.47 52.82
2016-06-30 13.39 30.61 35.74
2016-03-31 27.80 30.42 35.82
2015-12-31 47.72 30.18 51.56
2015-09-30 64.05 30.00 70.33
2015-06-30 76.09 30.00 94.37
2015-03-31 64.37 30.00 67.53
2014-12-31 75.64 30.00 72.77
2014-09-30 83.45 30.00 127.13
2014-06-30 90.09 30.00 132.11
2014-03-31 -5.72 30.00 31.39
2013-12-31 -1.13 30.00 38.06
2013-09-30 3.41 30.00 42.59
2013-06-30 -9.05 30.00 29.13
2013-03-31 -2.84 30.00 28.27
2012-12-31 -0.45 30.00 35.60
2012-09-30 9.78 30.00 41.02
2012-06-30 15.66 30.00 34.88
  • BioCryst Pharmaceuticals's level of debt (350.3%) compared to net worth is high (greater than 40%).
  • BioCryst Pharmaceuticals had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BioCryst Pharmaceuticals has sufficient cash runway for 1.1 years based on current free cash flow.
  • BioCryst Pharmaceuticals has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 20.4% each year.
X
Financial health checks
We assess BioCryst Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioCryst Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BioCryst Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioCryst Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of BioCryst Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioCryst Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioCryst Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:BCRX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2012 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:BCRX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioCryst Pharmaceuticals has not reported any payouts.
  • Unable to verify if BioCryst Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioCryst Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioCryst Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of BioCryst Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess BioCryst Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioCryst Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioCryst Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BioCryst Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jon Stonehouse
COMPENSATION $4,167,643
AGE 57
TENURE AS CEO 12.4 years
CEO Bio

Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co., Ltd. since joining in January 8, 2007 and also has been its President since July 13, 2007. Mr. Stonehouse has over 20 years strong commercialization, Financial transaction, Business development and Management experience. Previously, he served as Senior Vice President of Corporate Development of Merck KGaA, since July 2002 and was responsible for global licensing and business development, corporate mergers and acquisitions, corporate strategic planning and alliance management. Among his accomplishments, he was responsible for leading the effort to develop a strategy for Merck that significantly changed Merck. Since March 2002, he served as Vice President of Global Licensing and Business Development and Integration of Merck KGaA, where he was responsible for the worldwide licensing and business development activities for the Ethical Pharmaceutical Division of Merck KGaA. Mr. Stonehouse joined EMD Pharmaceuticals, Inc. (the US Ethical Pharma division for Merck KGaA) in December 1999 as Vice President, Licensing and Business Development - Strategy & Integration and IT. Prior to Merck KGaA, he held a variety of roles at Astra erck/AstraZeneca including: Customer Unit Director, Director, Marketing & Sales - IT, National Sales Manager, National Sales Director - Managed Healthcare and Product Director - Omeprazole and was responsible for all clinical development and commercial activity for PRILOSEC in US. He started his career in the pharmaceutical industry as a Sales Representative, National Sales Trainer and District Sales Manager for Merck & Co., Inc. Mr. Stonehouse serves as a Member of Advisory Board of Genscript Biotech Corporation. He serves as a Member of Advisory board at Precision BioSciences, Inc. He has been a Director of Bellicum Pharmaceuticals, Inc. since December 2014. Mr. Stonehouse holds BS in Microbiology from the University of Minnesota.

CEO Compensation
  • Jon's compensation has increased whilst company is loss making.
  • Jon's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the BioCryst Pharmaceuticals management team in years:

9.4
Average Tenure
52
Average Age
  • The average tenure for the BioCryst Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Jon Stonehouse

TITLE
CEO, President & Director
COMPENSATION
$4M
AGE
57
TENURE
12.4 yrs

Tom Staab

TITLE
CFO, Principal Accounting Officer
COMPENSATION
$2M
AGE
50
TENURE
7.9 yrs

Bill Sheridan

TITLE
Chief Medical Officer & Senior VP
COMPENSATION
$2M
AGE
63
TENURE
10.9 yrs

Yarlagadda Babu

TITLE
Senior Vice President of Drug Discovery
COMPENSATION
$2M
AGE
65
TENURE
5.7 yrs

Lynne Powell

TITLE
Chief Commercial Officer & Senior VP
COMPENSATION
$2M
AGE
51
TENURE
4.4 yrs

John Bluth

TITLE
Senior Vice President of Investor Relations & Corporate Communications
AGE
45

Alane Barnes

TITLE
Senior VP
COMPENSATION
$1M
AGE
52
TENURE
12.9 yrs

Robert Stoner

TITLE
Vice President of Human Resources

Elliott Berger

TITLE
Senior Vice President of Regulatory Affairs
Board of Directors Tenure

Average tenure and age of the BioCryst Pharmaceuticals board of directors in years:

7.4
Average Tenure
67
Average Age
  • The tenure for the BioCryst Pharmaceuticals board of directors is about average.
Board of Directors

Bob Ingram

TITLE
Chairman
COMPENSATION
$213K
AGE
76
TENURE
2.1 yrs

Jon Stonehouse

TITLE
CEO, President & Director
COMPENSATION
$4M
AGE
57
TENURE
12.4 yrs

Ken Lee

TITLE
Director
COMPENSATION
$201K
AGE
70
TENURE
8 yrs

Nancy Hutson

TITLE
Director
COMPENSATION
$191K
AGE
69
TENURE
7.4 yrs

George Abercrombie

TITLE
Independent Director
COMPENSATION
$181K
AGE
63
TENURE
7.7 yrs

Theresa Heggie

TITLE
Director
COMPENSATION
$193K
AGE
58
TENURE
0.5 yrs

Steve Aselage

TITLE
Director
AGE
67
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by BioCryst Pharmaceuticals insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
24. May 19 Buy Stephen Aselage Individual 22. May 19 22. May 19 3,000 $3.57 $10,710
14. Mar 19 Buy Stephen Aselage Individual 12. Mar 19 12. Mar 19 2,000 $8.30 $16,600
20. Dec 18 Sell William Sheridan Individual 18. Dec 18 18. Dec 18 -20,488 $7.58 $-155,299
06. Dec 18 Sell Thomas Staab Individual 04. Dec 18 04. Dec 18 -3,922 $9.45 $-37,063
04. Dec 18 Sell Alane Barnes Individual 30. Nov 18 30. Nov 18 -19,290 $9.07 $-174,960
X
Management checks
We assess BioCryst Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioCryst Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Are Analysts Bullish?

The most recent earnings announcement BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) released in December 2018 … that losses became smaller relative to the prior year's level

Simply Wall St -

Market Sentiment Around Loss-Making BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)

In this article, I will touch on the expectations for BCRX’s growth and when analysts expect the company to become profitable. … This means a double-digit growth rate is not unusual, especially if the company is currently in an investment period. … For a more comprehensive look at BCRX, take a look at BCRX’s company page on Simply Wall St.

Simply Wall St -

Brokers' Outlook On BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)

Two major red flags for BCRX are its high level of debt at 0.65x equity, and its high cash expenses leading to negative cash profit from operations. … BCRX has high near term liquidity, with short term assets (cash and other liquid assets) amply covering upcoming one-year liabilities, as well as long-term commitments. … One reason I do like BCRX as a business is its low level of fixed assets on its balance sheet (6.09% of total assets).

Simply Wall St -

What Should We Expect From BioCryst Pharmaceuticals Inc's (NASDAQ:BCRX) Earnings In The Year Ahead?

With net income at current levels of -US$65.78M, the consensus growth rate suggests that earnings will decline to -US$52.59M by 2019. … To understand the overall trajectory of BCRX's earnings growth over these next fews years, I've fitted a line through these analyst earnings forecast to determine an annual growth rate from the slope. … NasdaqGS:BCRX Future Profit Mar 6th 18 From the current net income level of -US$65.78M and the final forecast of -US$63.52M by 2021, the annual rate of growth for BCRX’s earnings is 12.43%.

Simply Wall St -

Was BioCryst Pharmaceuticals Inc's (NASDAQ:BCRX) Earnings Growth Better Than The Industry's?

After reading BioCryst Pharmaceuticals Inc's (NASDAQ:BCRX) most recent earnings announcement (30 September 2017), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … View our latest analysis for BioCryst Pharmaceuticals Commentary On BCRX's Past Performance I prefer to use the ‘latest twelve-month’ data, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … Each year, for the past five years BioCryst Pharmaceuticals's top-line has increased by a mere 2.72%, on average.

Simply Wall St -

Is BioCryst Pharmaceuticals Inc (BCRX) A Healthcare Industry Laggard Or Leader?

As a future industry laggard in growth, BCRX may be a cheaper stock relative to its peers. … BCRX is a biotech industry laggard in terms of its future growth outlook. … If your initial investment thesis is around the growth prospects of BCRX, there are other biotech companies that are expected to deliver higher growth in the future, and perhaps trading at a discount to the industry average.

Simply Wall St -

How Does BioCryst Pharmaceuticals Inc (BCRX) Affect Your Portfolio Returns?

Generally, an investor should consider two types of risk that impact the market value of BCRX. … A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … BCRX, with its market capitalisation of USD $460.19M, is a small-cap stock, which generally have higher beta than similar companies of larger size.

Simply Wall St -

Company Info

Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Details
Name: BioCryst Pharmaceuticals, Inc.
BCRX
Exchange: NasdaqGS
Founded: 1986
$407,054,678
110,312,921
Website: http://www.biocryst.com
Address: BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard,
Suite 200,
Durham,
North Carolina, 27703,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS BCRX Common Stock Nasdaq Global Select US USD 04. Mar 1994
DB BO1 Common Stock Deutsche Boerse AG DE EUR 04. Mar 1994
BMV BCRX * Common Stock Bolsa Mexicana de Valores MX MXN 04. Mar 1994
Number of employees
Current staff
Staff numbers
100
BioCryst Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/23 23:33
End of day share price update: 2019/06/21 00:00
Last estimates confirmation: 2019/05/30
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.